Dyslipidemia testing: Why, for whom and when

被引:2
|
作者
Galema-Boers, J. M. H. [1 ]
van Lennep, J. E. Roeters [1 ]
机构
[1] Erasmus Univ, Dept Internal Med, Med Ctr, Pharmacol Vasc & Metab Dis Sect, Rotterdam, Netherlands
关键词
Cardiovascular disease; Dyslipidemia; Familial; hypercholesterolemia; Lipid testing; screening; Guidelines; CARDIOVASCULAR-DISEASE; RISK; PREVENTION; GUIDELINES;
D O I
10.1016/j.maturitas.2015.05.012
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Dyslipidemia is a major risk factor for cardiovascular disease. This review addresses why, who and when to test for dyslipidemia. The essence why to test lipids is that those individuals recognized to potentially benefit from primary cardiovascular risk prevention, have a complete cardiovascular risk assessment. Who and when to test lipids differs among the major European, English and American guidelines regarding the recommended age and approach. It is important to note that the threshold and the frequency in whom to perform risk assessment is not established. Most important in decisions concerning lipid testing is communication and to involve individual circumstances. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:442 / 445
页数:4
相关论文
共 50 条
  • [1] Advanced Lipid Testing: When, Why, and In Whom?
    Watson, Karol E.
    Stocker, Eric H.
    Jacoby, Douglas S.
    McCullough, Peter A.
    [J]. REVIEWS IN CARDIOVASCULAR MEDICINE, 2014, 15 (04) : 311 - 319
  • [2] The Return of Results in Genetic Testing: Who Owes What to Whom, When, and Why?
    Alessi, Stephanie A.
    [J]. HASTINGS LAW JOURNAL, 2013, 64 (06) : 1697 - 1726
  • [3] Size matters but when, why and for whom?
    Blackwell, Anna K. M.
    Lee, Ilse
    Scollo, Michelle
    Wakefield, Melanie
    Munafo, Marcus R.
    Marteau, Theresa M.
    [J]. ADDICTION, 2020, 115 (05) : 815 - 816
  • [4] ARTHROGRAPHY FOR RHEUMATIC DISEASE - WHEN, WHY, AND FOR WHOM
    GOLDMAN, AB
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1991, 17 (03) : 505 - 542
  • [5] Making sense of refractive surgery in 2001: Why, when, for whom, and by whom?
    Mannis, MJ
    Segal, WA
    Darlington, JK
    [J]. MAYO CLINIC PROCEEDINGS, 2001, 76 (08) : 823 - 829
  • [6] Tranexamic acid for childbirth: why, when, and for whom
    Sentilhes, Loic
    Madar, Hugo
    Mattuizzi, Aurelien
    Froeliger, Alizee
    Merlot, Benjamin
    Elleboode, Benoit
    Deneux-Tharaux, Catherine
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (09) : 753 - 761
  • [7] Antibiotic prophylaxis in COPD: Why, when, and for whom?
    Miravitlles, Marc
    Anzueto, Antonio
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 32 : 119 - 123
  • [8] Laparoscopic myomectomy today - Why, when and for whom?
    Nezhat, F
    Seidman, DS
    Nezhat, C
    Nezhat, CH
    [J]. HUMAN REPRODUCTION, 1996, 11 (05) : 933 - 934
  • [9] Conservative Kidney Management: When, Why, and For Whom?
    Li, Kelly Chenlei
    Brown, Mark Ashley
    [J]. SEMINARS IN NEPHROLOGY, 2023, 43 (01)
  • [10] Who cares? For whom and when, how, and why?
    Berscheid, E
    Collins, WA
    [J]. PSYCHOLOGICAL INQUIRY, 2000, 11 (02) : 107 - 109